A major review of GLP-1 drugs takes a closer look at the risks and rewards
Moderate-to-high-quality evidence from umbrella reviews on non-cardiometabolic outcomes supported associations between GLP-1 therapy and risks of nausea, vomiting, and diarrhea. High-quality evidence indicates a possible protective association between GLP-1 medication and infection-related outcomes, particularly serious infections. Exploratory indications also suggest a possible reduction in the risk of falls, respiratory disease events, and all-cause dementia. A … Read more
